Immunethep is a biotech startup company (spin-off from the University of Porto) that is developing anti-bacterial immunotherapies based on the discovery of a virulence mechanism shared by different bacteria that cause life-threatening infections.
The first product, PNV1 - Paragon Novel Vaccine, is a preventive strategy that will confer a robust protection against the main life threatening bacterial infections, including multi-resistant strains. PNV1 will be the first vaccine able to prevent multi-bacterial infections from all its serotypes from the womb until elderhood.
The first product, PNV1 - Paragon Novel Vaccine, is a preventive strategy that will confer a robust protection against the main life threatening bacterial infections, including multi-resistant strains. PNV1 will be the first vaccine able to prevent multi-bacterial infections from all its serotypes from the womb until elderhood.
Location: Portugal, Cantanhede
Employees: 11-50
Founded date: 2014
Investors 3
| Date | Name | Website |
| - | Venture Ca... | venture-ca... |
| - | Portugal V... | portugalve... |
| 06.09.2025 | CARB-X | carb-x.org |